These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9552949)

  • 41. Is High Serum LDL/HDL Cholesterol Ratio an Emerging Risk Factor for Sudden Cardiac Death? Findings from the KIHD Study.
    Kunutsor SK; Zaccardi F; Karppi J; Kurl S; Laukkanen JA
    J Atheroscler Thromb; 2017 Jun; 24(6):600-608. PubMed ID: 27784848
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).
    Frey P; Waters DD; DeMicco DA; Breazna A; Samuels L; Pipe A; Wun CC; Benowitz NL
    Am J Cardiol; 2011 Jan; 107(2):145-50. PubMed ID: 21129718
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy.
    Hong MK; Lee CW; Kim YH; Park DW; Lee SW; Park CB; Jang JS; Han KH; Cheong SS; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2006 Oct; 98(7):866-70. PubMed ID: 16996864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Even at LDL cholesterol 100mg/dl. "Every coronary disease patient has to receive a statin"].
    MMW Fortschr Med; 2003 Dec; 145(49):57. PubMed ID: 14963997
    [No Abstract]   [Full Text] [Related]  

  • 45. [Lipid profile in 4 minutes. Impressing your coronary heart disease patients].
    Janssen K
    MMW Fortschr Med; 2000 Jul; 142(26-27):39. PubMed ID: 10929482
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
    Burton JR; Teo KK; Buller CE; Plante S; Catellier D; Tymchak W; Taylor D; Dzavik V; Montague TJ;
    Can J Cardiol; 2003 Apr; 19(5):487-91. PubMed ID: 12717482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.
    Alemao E; Yin D; Sintonen H; Salomaa V; Jousilahti P
    Am J Cardiovasc Drugs; 2006; 6(5):349-55. PubMed ID: 17083270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?].
    Alexa ID; Panaghiu L; Ungureanu G
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(4):721-6. PubMed ID: 16610166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry.
    Shiiba M; Zhang B; Miura SI; Ike A; Nose D; Kuwano T; Imaizumi S; Sugihara M; Iwata A; Nishikawa H; Kawamura A; Shirai K; Yasunaga S; Saku K
    Heart Vessels; 2018 Feb; 33(2):102-112. PubMed ID: 28815384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).
    Pedersen TR; Kjekshus J; Pyörälä K; Olsson AG; Cook TJ; Musliner TA; Tobert JA; Haghfelt T
    Am J Cardiol; 1998 Feb; 81(3):333-5. PubMed ID: 9468077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of hydroxychloroquine on cholesterol synthesis depends on the profile of cholesterol metabolism. A controlled clinical study.
    Simonen P; Ulander L; Eklund KK; Niemi M; Backman JT; Gylling H; Sinisalo J;
    Atheroscler Plus; 2024 Mar; 55():93-97. PubMed ID: 38487037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cholesterol-metabolism, plant sterols, and long-term cognitive decline in older people - Effects of sex and APOEe4.
    Spinedi M; Clark C; Zullo L; Kerksiek A; Pistis G; Castelao E; von Gunten A; Preisig M; Lütjohann D; Popp J
    iScience; 2024 Feb; 27(2):109013. PubMed ID: 38327787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Higher Cholesterol Absorption Marker at Baseline Predicts Fewer Cardiovascular Events in Elderly Patients Receiving Hypercholesterolemia Treatment: The KEEP Study.
    Kuwabara M; Sasaki J; Ouchi Y; Oikawa S; Nakagawa K; Sato M; Koba S; Kono S; Saikawa T; Arai H
    J Am Heart Assoc; 2024 Feb; 13(3):e031865. PubMed ID: 38240241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxy- and Phytosterols as Biomarkers: Current Status and Future Perspectives.
    Olkkonen VM; Gylling H
    Adv Exp Med Biol; 2024; 1440():353-375. PubMed ID: 38036889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk?
    Anagnostis P; Kotsis V; Banach M; Mikhailidis DP
    Metabolites; 2023 Jan; 13(2):. PubMed ID: 36837764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel").
    Makhmudova U; Samadifar B; Maloku A; Haxhikadrija P; Geiling JA; Römer R; Lauer B; Möbius-Winkler S; Otto S; Schulze PC; Weingärtner O
    Clin Res Cardiol; 2023 Sep; 112(9):1212-1219. PubMed ID: 36602598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between Serum Oxysterols and Coronary Plaque Regression during Lipid-Lowering Therapy with Statin and Ezetimibe: Insights from the CuVIC Trial.
    Nakano Y; Yamamoto M; Matoba T; Katsuki S; Nakashiro S; Takase S; Akiyama Y; Nagata T; Mukai Y; Inoue S; Oi K; Higo T; Takemoto M; Suematsu N; Eshima K; Miyata K; Usui M; Sadamatsu K; Kadokami T; Hironaga K; Ichi I; Todaka K; Kishimoto J; Tsutsui H
    J Atheroscler Thromb; 2023 Aug; 30(8):907-918. PubMed ID: 36450458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.
    Yanai H; Adachi H; Hakoshima M; Katsuyama H
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients.
    Vecka M; Dušejovská M; Staňková B; Rychlík I; Žák A
    Metabolites; 2021 Nov; 11(11):. PubMed ID: 34822432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.